Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Decision brief
Answer first · skim in under a minute
Structured plan for Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Lonvoguran ziclumeran (lonvo-z) delivered additional Phase 3 HAELO results on June 13, 2026 in a late-breaking EAACI oral session in Istanbul. The CRISPR HAE candidate cut mean monthly attacks by 87% versus placebo in NCT06634420, with simultaneous New England Journal of Medicine publication.
Contents9 sections
Key Takeaways
- HAELO (NCT06634420) enrolled 80 patients; start January 15, 2025; primary completion February 10, 2026 (ClinicalTrials.gov).
- Primary endpoint: 87% reduction in mean monthly attacks vs placebo in weeks 5–28 (p<0.0001), per Intellia’s June 13, 2026 release.
- Key secondary: 62% of lonvo-z patients attack-free and therapy-free vs 11% on placebo over the six-month efficacy window.
- Company said a rolling BLA began in April 2026 and still targets U.S. approval/launch in the first half of 2027—subject to FDA review.
What did Intellia present at EAACI 2026?
On June 13, 2026, Intellia’s GlobeNewswire release said additional HAELO Phase 3 results for lonvo-z were shown in a late-breaking oral session at EAACI 2026 in Istanbul, Türkiye.
The same day, results were published in the New England Journal of Medicine (HAELO ClinicalTrials.gov number NCT06634420). That pairing—congress oral plus NEJM—matters for how payers and HTA bodies weight durability claims.
How is HAELO designed?
ClinicalTrials.gov NCT06634420 titles the study HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema. Status is ACTIVE_NOT_RECRUITING; phase PHASE3; actual enrollment 80.
- Design: randomized, double-blind, placebo-controlled, single IV infusion.
- Drug: lonvo-z / NTLA-2002 (in vivo CRISPR editing of KLKB1).
- Efficacy window cited by sponsor: weeks 5 to 28 after dosing.
- Earlier Phase 1/2 work used a separate registry (NCT05120830) and should not be confused with HAELO when citing enrollment or dose.
Which efficacy numbers are now public?
Intellia previously reported the primary endpoint: 87% reduction in mean monthly attacks versus placebo (p<0.0001) in weeks 5–28. It also reported 62% vs 11% attack-free and therapy-free rates for lonvo-z vs placebo over that period (p<0.0001).
The June 13 update focused on other key secondary endpoints (including on-demand treatment use and moderate-to-severe attacks). Exact secondary point estimates should be taken from the NEJM paper and congress slides rather than secondary news summaries.
What is the regulatory path?
Intellia said a rolling biologics license application was started in April 2026 with FDA and that it still anticipates U.S. approval and launch in the first half of 2027. Those are company timelines, not agency decisions.
Lonvo-z has collected multiple designations (including FDA RMAT/Orphan and EMA PRIME per the company release). Designations speed dialogue; they do not guarantee approval.
For EU strategy teams, a one-time gene-editing product will still face Joint Clinical Assessment evidence questions on long-term attack control, re-treatment rules if any, and comparison with oral or injectable prophylaxis. HAELO’s six-month efficacy window is a start, not the full HTA story.
Investors should separate three clocks: (1) NEJM/EAACI scientific validation in June 2026, (2) rolling BLA review milestones through 2026–2027, and (3) payer policy build after a potential first-half-2027 U.S. launch. Slippage on any clock changes peak-year models more than a single secondary endpoint slide.
What remains unproven for HAE markets?
Long-term attack control beyond the primary observation period, real-world safety of permanent KLKB1 editing, and pricing versus oral and injectable prophylactics are still open. EAACI data do not settle EU Joint Clinical Assessment or U.S. payer criteria.
Do not treat Phase 1/2 NCT05120830 enrollment (37) as Phase 3 HAELO evidence. Keep registries separate when modeling peak share against oral and injectable prophylactics.
Analysts should also track whether post-week-28 crossover and long-term observation data change the attack-free rates that drove the June 13 secondary endpoint discussion.
Related NovaPharma coverage
- BioCryst ORLADEYO and navenibart HAE data at EAACI 2026
- Hereditary angioedema disease hub
- EMEA 2026 life sciences cluster report
Frequently Asked Questions
What is lonvoguran ziclumeran (lonvo-z)?
Lonvo-z (formerly NTLA-2002) is Intellia’s investigational in vivo CRISPR gene-editing therapy designed to inactivate KLKB1 and lower plasma kallikrein for hereditary angioedema. It is studied as a one-time intravenous infusion.
What is the HAELO Phase 3 trial?
HAELO (NCT06634420) is a randomized, double-blind, placebo-controlled Phase 3 study of NTLA-2002/lonvo-z in hereditary angioedema. ClinicalTrials.gov lists actual enrollment of 80 participants.
What primary endpoint result did Intellia report for HAELO?
Intellia reported an 87% reduction (p<0.0001) in mean monthly HAE attacks for lonvo-z versus placebo during weeks 5–28, and said 62% of lonvo-z patients were attack-free and therapy-free versus 11% on placebo over that period.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Lonvoguran Ziclumeran.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
